Joint Steering Committee. Within ​ after the Effective Date, the Parties shall form a Joint Steering Committee (the “JSC”) to facilitate the transfer of information and coordinate processes related to the development, Regulatory Approval and Commercialization of the SYROS Products and the QIAGEN IVDs being the subject of this Agreement. The JSC shall be composed of ​ representatives appointed by each Party, at least ​ of which shall be different than members of the JPT. Each representative shall be appointed (and may be replaced at any time) by a Party upon prior written notice to the other Party. These representatives shall have appropriate experience, knowledge, and ongoing familiarity with the Projects in their then current phases.

No later than ​ prior to the anticipated date on which the first Regulatory Approval of a SYROS Product is expected, the Parties will form a joint commercialization team (the “Joint Commercialization Committee” or “JCC”). The JCC will (as considered reasonable by each Party, in its sole discretion and to the extent legally allowed), discuss a coordinated approach for the sales and marketing of the QIAGEN IVD for use with the SYROS Product. Such JCC shall be constituted and shall operate as the JSC determines and as may be outlined in the relevant Schedule.